Trial Profile

HYPAZ: An Open-label Investigation Into Hypertension Induced by Pazopanib Therapy

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 28 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pazopanib (Primary)
Indications Advanced breast cancer; Carcinoma; Cervical cancer; Gastrointestinal cancer; Glioblastoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Skin cancer; Small cell lung cancer; Soft tissue sarcoma; Uveal melanoma
Focus Adverse reactions
Acronyms HYPAZ

Most Recent Events

20 Jul 2015 Planned End Date changed from 1 Sep 2018 to 1 Sep 2015 as per ClinicalTrials.gov record.
20 Jul 2015 Status changed from completed to discontinued as per ClinicalTrials.gov record..
18 Oct 2014 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com